IYH - iShares US Healthcare ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
181.76
-1.44 (-0.79%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close183.20
Open185.26
Bid177.41 x 1400
Ask184.69 x 1000
Day's Range180.00 - 185.26
52 Week Range166.89 - 204.83
Volume163,016
Avg. Volume148,925
Net Assets2.54B
NAV200.78
PE Ratio (TTM)N/A
Yield1.03%
YTD Return16.15%
Beta (3Y Monthly)0.98
Expense Ratio (net)0.43%
Inception Date2000-06-12
Trade prices are not sourced from all markets
  • Best ETFs: With Health Care Leading, IShares ETF Comes Out A Winner
    Investor's Business Daily4 days ago

    Best ETFs: With Health Care Leading, IShares ETF Comes Out A Winner

    In a lackluster year for stocks, health care proved to be one of the best sectors, a big reason why iShares U.S. Healthcare is now among the best ETFs.

  • ETF Trends22 days ago

    10 Sector ETFs That Could Stand Out in the New Year

    The U.S. equity rally is beginning to lose steam and investors should not expect markets to maintain their breakneck spurt of yesteryear. Nevertheless, traders may still find value in some battered sectors ...

  • ETF Trends28 days ago

    Stable, Defensive Sector ETFs for a Wobbly Market

    As U.S. markets continue to wobble, investors who want to stay in the game can look to defensive sector-related ETFs for a more steady approach. “If the sell-off continues and it deepens, it’s going to ...

  • ETF Trendslast month

    Leveraged Healthcare ETF Gains On Midterm Election Results

    Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...

  • ETF Trendslast month

    Healthcare ETFs in Focus Ahead of Election Day

    Count the iShares US Medical Devices ETF (NYSEArca: IHI) and the iShares US Healthcare ETF (NYSEArca: IYH) among the healthcare exchange traded funds that could be affected by the results of the upcoming ...

  • Pfizer’s Market Cap and Shareholding Pattern
    Market Realist2 months ago

    Pfizer’s Market Cap and Shareholding Pattern

    As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.

  • ETF Trends2 months ago

    Health Care ETFs Retreat on DOJ Approval of Aetna-CVS Merger

    The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.

  • Best ETFs & Stocks From the Top Sector of Q3
    Zacks3 months ago

    Best ETFs & Stocks From the Top Sector of Q3

    Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

  • AbbVie’s Dividend Has Risen 140% since 2013
    Market Realist3 months ago

    AbbVie’s Dividend Has Risen 140% since 2013

    AbbVie (ABBV) announced its fourth-quarter dividend yield of 4.09%. On September 7, AbbVie announced a dividend of $0.96 per share to its shareholders of record on October 15.

  • Thermo Fisher to Offer Complete Cannabis Testing Solutions
    Market Realist3 months ago

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

  • How Abiomed’s Revenue Trended in the First Quarter
    Market Realist3 months ago

    How Abiomed’s Revenue Trended in the First Quarter

    As discussed earlier, Abiomed (ABMD) reported revenues of $180.0 million in Q1 2019, a 36% increase as compared to revenues of ~$132.5 million in the first quarter of 2018.

  • Investopedia4 months ago

    3 ETFs for Johnson & Johnson's Healthy Breakout

    Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, has underperformed the broader market in 2018. The company's stock is down 3.66% year to date (YTD), while the Standard and Poor's 500 index (S&P 500) is up roughly 7%. David Katz, chief investment officer at Matrix Asset Advisors, told Reuters, "We are much more upbeat about Johnson & Johnson today than we were six months ago.

  • 4 Sector ETFs to Tap at New Highs
    Zacks4 months ago

    4 Sector ETFs to Tap at New Highs

    While there are winners in many corners of the stock market, investors should tap the sectors that are expected to continue moving higher in the weeks ahead.

  • Estimates and Recommendations for Allergan in August
    Market Realist4 months ago

    Estimates and Recommendations for Allergan in August

    Analysts expect Allergan’s (AGN) adjusted EPS to be $16.29 on revenue of $15.53 billion in 2018, a 2.6% fall in revenue compared to $15.94 billion in 2017. Analysts expect the company’s adjusted net income to fall in 2018 mainly due to a fall in its gross profit margin and partially offset by a decrease in its selling, general, and administrative expenses as well as its research and development expenses. Allergan’s stock price has fallen nearly 20.2% over the last 12 months, but it’s risen ~12.8% year-to-date in 2018.

  • ETF Trends5 months ago

    Health Care ETFs Respond Positively to Jobs Report

    The latest June jobs report published by the Bureau of Labor Statistics showed an increase of 215,000 jobs--9.2 percent higher than original forecasts--with health services being one of the top beneficiaries of the increase. The jobs report revealed that the education and health services sector represented the biggest net job gainer for June--54,000 new positions created. Of that number, about 25,000 came as a result of hiring in the health care sector.

  • How Incyte’s Jakafi Performed in Q1 2018
    Market Realist7 months ago

    How Incyte’s Jakafi Performed in Q1 2018

    Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.

  • Allergan’s International Business in 1Q18
    Market Realist7 months ago

    Allergan’s International Business in 1Q18

    Allergan’s (AGN) International business includes the revenues from both specialized therapeutics portfolio and general products portfolio from outside the US markets.

  • Eli Lilly’s Valuation after Its 1Q18 Earnings
    Market Realist8 months ago

    Eli Lilly’s Valuation after Its 1Q18 Earnings

    Eli Lilly (LLY) surpassed Wall Street analysts’ estimates for EPS (earnings per share) and revenues in 1Q18. Reported EPS was $1.34 on revenues of $5.7 billion, compared to the estimate for EPS of $1.14 on revenues of $5.5 billion.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist8 months ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • Johnson & Johnson’s Revenue Estimates for 1Q18
    Market Realist8 months ago

    Johnson & Johnson’s Revenue Estimates for 1Q18

    As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.

  • Key Updates on Akcea Therapeutics’ Volanesorsen
    Market Realist9 months ago

    Key Updates on Akcea Therapeutics’ Volanesorsen

    How Ionis Pharmaceuticals Is Positioned in 2018

  • ETF Trends10 months ago

    Healthcare Dip Could be a Buying Opportunity

    The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...

  • Merck’s 4Q17 Estimates: Revenue Growth Expected
    Market Realist11 months ago

    Merck’s 4Q17 Estimates: Revenue Growth Expected

    Expectations for Merck’s 4Q17 Earnings on February 2

  • Merck & Co.’s Human Vaccines Business in 3Q17
    Market Realist11 months ago

    Merck & Co.’s Human Vaccines Business in 3Q17

    Who’s Watching Merck & Co. in January 2018?

  • Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect
    Market Realist11 months ago

    Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect

    Johnson & Johnson’s 4Q17 Earnings on January 23: What to ExpectA look at Johnson & Johnson’s estimates